High Levels of Circulating IL-10 in Human Malaria

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1994 Feb 1

PMID 8306505

Citations 46

Authors

F Peyron

N Burdin

P Ringwald

J P Vuillez

F Rousset

J Banchereau

Affiliations

Soon will be listed here.

Abstract

IL-10 is a monocyte/lymphocyte derived cytokine which has been shown to inhibit certain cellular immune responses such as delayed hypersensitivity. In particular, the production of tumour necrosis factor (TNF), IL-1 and IL-6, which are involved in malaria pathology, are strongly inhibited by IL-10. Accordingly, we examined whether IL-10 could be involved in a human acute parasitic infection such as Plasmodium falciparum malaria. Human IL-10 levels in plasma were determined by two-site ELISA method, taking care to avoid non-specific reactions due to autoantibodies. Fourteen cerebral, 11 severe, and 20 mild malaria cases had mean IL-10 levels of 2812, 2882 and 913 pg/ml, respectively, while 98% of healthy individuals had undetectable (less than 100 pg/ml) circulating IL-10. Thirteen of the 25 cerebral/severe cases had > 2000 pg/ml. In 11 hospitalized patients, circulating IL-10 levels were found to return to virtually normal levels 7 days after antimalarial chemotherapy when biological and clinical malaria features had disappeared (mean levels fell from 3880 to 333 pg/ml). Further studies are required to determine whether these elevated levels of IL-10 play a beneficial role by reducing the parasite-induced inflammatory response, or a detrimental one by decreasing the cellular immune responses.

Citing Articles

Clinical, immune and genetic risk factors of malaria-associated acute kidney injury in Zambian children: A study protocol.

Mwaba C, Munsaka S, Mwakazanga D, Rutagwerae D, Ngalamika O, Mwanza S PLoS One. 2025; 20(2):e0316205.

PMID: 39913368 PMC: 11801570. DOI: 10.1371/journal.pone.0316205.

An integrated approach to predict genetic risk for Mosquito-Borne diseases in the local Population of Tehsil Haripur, Khyber Pakhtunkhwa, Pakistan.

Basri R, Aqeel M, Awan F, Khan S, Obaid A, Parveen R Sci Rep. 2025; 15(1):3478.

PMID: 39875533 PMC: 11775262. DOI: 10.1038/s41598-025-88095-0.

Screening Clinical, Laboratory and Host Markers for Diagnosis of Disease Severity in Clinical Samples.

Arya A, Chaudhry S, Yadav K, Tamang S, Meena S, Matlani M Indian J Microbiol. 2024; 64(3):1278-1289.

PMID: 39282159 PMC: 11399495. DOI: 10.1007/s12088-024-01324-4.

Neutrophils versus Protozoan Parasites: , , , , and .

Uribe-Querol E, Rosales C Microorganisms. 2024; 12(4).

PMID: 38674770 PMC: 11051968. DOI: 10.3390/microorganisms12040827.

Relation between Increased IL-10 Levels and Malaria Severity: A Systematic Review and Meta-Analysis.

Sornsenee P, Wilairatana P, Kotepui K, Masangkay F, Romyasamit C, Kotepui M Trop Med Infect Dis. 2023; 8(1).

PMID: 36668942 PMC: 9865813. DOI: 10.3390/tropicalmed8010035.

References

Greenwood B, MULLER A, VALKENBURG H . Rheumatoid factor in Nigerian sera. Clin Exp Immunol. 1971; 9(2):161-73. PMC: 1713025. View

Blay J, Burdin N, Rousset F, Lenoir G, Biron P, Philip T . Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood. 1993; 82(7):2169-74. View

Grau G, Taylor T, Molyneux M, Wirima J, Vassalli P, Hommel M . Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med. 1989; 320(24):1586-91. DOI: 10.1056/NEJM198906153202404. View

Kern P, Hemmer C, Van Damme J, Gruss H, Dietrich M . Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med. 1989; 87(2):139-43. DOI: 10.1016/s0002-9343(89)80688-6. View

Brewster D, Kwiatkowski D, White N . Neurological sequelae of cerebral malaria in children. Lancet. 1990; 336(8722):1039-43. DOI: 10.1016/0140-6736(90)92498-7. View

Kwiatkowski D, Hill A, Sambou I, Twumasi P, Castracane J, Manogue K . TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet. 1990; 336(8725):1201-4. DOI: 10.1016/0140-6736(90)92827-5. View

Heinzel F, Sadick M, Mutha S, Locksley R . Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A. 1991; 88(16):7011-5. PMC: 52223. DOI: 10.1073/pnas.88.16.7011. View

Sher A, Fiorentino D, Caspar P, Pearce E, Mosmann T . Production of IL-10 by CD4+ T lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth infection. J Immunol. 1991; 147(8):2713-6. View

de Waal Malefyt R, Haanen J, Spits H, Roncarolo M, Te Velde A, Figdor C . Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991; 174(4):915-24. PMC: 2118975. DOI: 10.1084/jem.174.4.915. View

10.

Bogdan C, Vodovotz Y, Nathan C . Macrophage deactivation by interleukin 10. J Exp Med. 1991; 174(6):1549-55. PMC: 2119047. DOI: 10.1084/jem.174.6.1549. View

11.

Silva J, Morrissey P, Grabstein K, Mohler K, Anderson D, Reed S . Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med. 1992; 175(1):169-74. PMC: 2119081. DOI: 10.1084/jem.175.1.169. View

12.

Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J . Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med. 1992; 175(3):671-82. PMC: 2119142. DOI: 10.1084/jem.175.3.671. View

13.

Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu D . Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A. 1992; 89(5):1890-3. PMC: 48559. DOI: 10.1073/pnas.89.5.1890. View

14.

Harpaz R, Edelman R, Wasserman S, Levine M, Davis J, Sztein M . Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge. J Clin Invest. 1992; 90(2):515-23. PMC: 443129. DOI: 10.1172/JCI115889. View

15.

Abrams J, Roncarolo M, Yssel H, Andersson U, Gleich G, Silver J . Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev. 1992; 127:5-24. DOI: 10.1111/j.1600-065x.1992.tb01406.x. View

16.

Yssel H, de Waal Malefyt R, Roncarolo M, Abrams J, Lahesmaa R, Spits H . IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol. 1992; 149(7):2378-84. View

17.

Merville P, Rousset F, Banchereau J, Klein B, Betaille R . Serum interleukin 10 in early stage multiple myeloma. Lancet. 1992; 340(8834-8835):1544-5. DOI: 10.1016/0140-6736(92)92795-h. View

18.

Burdin N, Peronne C, Banchereau J, Rousset F . Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med. 1993; 177(2):295-304. PMC: 2190909. DOI: 10.1084/jem.177.2.295. View

19.

Chomarat P, Rissoan M, Banchereau J, Miossec P . Interferon gamma inhibits interleukin 10 production by monocytes. J Exp Med. 1993; 177(2):523-7. PMC: 2190918. DOI: 10.1084/jem.177.2.523. View

20.

Grau G, Fajardo L, Piguet P, Allet B, Lambert P, Vassalli P . Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science. 1987; 237(4819):1210-2. DOI: 10.1126/science.3306918. View